Intacs Prescription Inserts for Keratoconus Patients
INTACS® Prescription Inserts Used to Treat Patients With Keratoconus as a Humanitarian Use Device
University of Texas Southwestern Medical Center
25 participants
Jan 1, 2011
INTERVENTIONAL
Conditions
Summary
The US food and Drug Administration (FDA) originally approved INTACS prescription inserts in April 1999 for the correction of low levels of nearsightedness (-1.00 to -3.00 diopters). Additional clinical data have shown that INTACS are safe for the treatment of keratoconus, in July 2004, FDA approved INTACS inserts for the treatment of keratoconus as a Humanitarian Use Device (FDA approval letter attached). The statute and the implementing regulation of FDA (21 CFR 814.124 (aj) require IRB review and approval before a HUD is used.INTACS prescription inserts are composed of two clear segments, each having an arc length of 150°, they are manufactured form a biomedical material called polymethylmethacrylate (PMMA) and are available in three thicknesses. Two INTACS inserts ranging from 0.250mm to 0.350mm may be implanted depending on the orientation of the cone and the amount of myopia and astigmatism to be reduced.
Eligibility
Inclusion Criteria1
- Who have experienced a progressive deterioration in their vision, such thot they can no longer achieve adequate functional vision on a daily basis with their contact lenses or spectacles; Who are 21 years of age or older; Who have clear central corneas; Who have a corneal thickness of 450 microns or greater at the proposed incision site; Who have corneal transplantation as the only remaining option to improve their functional vision.
Exclusion Criteria5
- Who have abnormally thin corneas or who have a corneal thickness of 449 microns or less at the proposed incision site;
- Patients with collagen vascular, autoimmune or immunodeficiency disease;
- Pregnant or nursing patients;
- Presence of ocular conditions, such as recurrent corneal erosion syndrome or corneal dystrophy, that my predispose the patient to future complications;
- Patients who are taking on or more of following medications: isotretinoin (Accutane); amiodarone HCL (Cordarone).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
INTACS® prescription inserts are an ophthalmic medical device designed for the reduction or elimination of myopia and astigmatism in patients with keratoconus so that their functional vision may be restored and the need for a corneal transplant procedure can potentially be deferred.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02138669